{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44"}]}],"title":"At least one TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"34"}]}],"title":"Grade 3 or higher TEAEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"25"}]}],"title":"Serious TEAEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"41"}]}],"title":"Treatment-related TEAEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"43"}]}],"title":"TEAEs of special interest"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"TEAEs leading to study drug discontinuation"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}],"title":"TEAEs leading to treatment interruption"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"TEAEs leading to dose reduction"}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"}],"units":"Participants"}],"description":"Number of participants with treatment-emergent adverse events (TEAEs), grade 3 or higher TEAEs, serious adverse events (SAEs), treatment-related adverse events (AEs), adverse events of special interest, and TEAEs leading to study drug discontinuation, dose reduction and treatment interruption","groups":[{"description":"Zanubrutinib 160 mg orally twice daily with or without food until progressive disease or intolerable toxicity","id":"OG000","title":"Zanubrutinib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The Safety Analysis Set included all participants who received ≥ 1 dose of study drug","reportingStatus":"POSTED","timeFrame":"Up to approximately 3 years and 5 months","title":"Number of Participants With Adverse Events","type":"SECONDARY","unitOfMeasure":"Participants"}